Efficacy of Massage with Roghan-i-Laqwa in Neuropathy

Efficacy of Dalk-i-Mutadil with Roghan-i-Laqwa versus Gabapentin in Distal Symmetric Polyneuropathy (DSPN) of Diabetic Origin - A Randomized Controlled Clinical Trial - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/06/069563

Enrollment

Registered

2024-06-26

Start date

Unknown

Completion date

Unknown

Last updated

2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E084- Diabetes mellitus due to underlying condition with neurological complications

Interventions

Intervention1: Dalk-i- Mutadil/Massage: Subjects in the test group will be treated by Dalk-i-Mu‘tadil with Roghan-i-Laqwa on the both legs (from knee to toe) for 20 minutes daily for 30 days. Dalk wi

Eligibility

Inclusion criteria

Inclusion criteria: Diagnosed patients of Distal Symmetrical Peripheral Neuropathy (DSPN) either by Type 1 or type 2 diabetes mellitus (HbA1c less than 9.5 percent) Patients of either gender Patients older than 20 years and less than 60 years of age

Exclusion criteria

Exclusion criteria: ? Pregnancy and lactation. ? Patients of peripheral neuropathy other than the Diabetic origin. ? Patients of DSPN due to Diabetes Mellitus having HbA1c more than 9.5% ? Currently participating in another clinical study in which the subject is or will be exposed to an investigational or non-investigational drug or device. ? Pathological state such as cardiovascular diseases, renal diseases, and hepatic diseases (having abnormal Serum bilirubin, Serum creatinine, Blood urea, AST, ALT and ECG). ? Any localized skin lesion over the legs (where integrity of skin is compromised) ? Unwillingness or inability to comply with the requirements of the protocol.

Design outcomes

Primary

Measure	Time frame
Visual analogue scale Vibration perception threshold (VPT) ? Michigan neuropathy screening instrument ? Chronic Acquired Polyneuropathy Patient-Reported Index (CAPPRI) Timepoint: 0th, 15th, 30th	—

Secondary

Measure	Time frame
No Secondary OutcomeTimepoint: N/A	—

Countries

India

Contacts

Public ContactDr Mohd Nayab

National Institute of Unani Medicine

nayabdr@gmail.com9019080556

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026